NCT04088084 is a Phase 2 clinical trial of palmitoylethanolamide (PEA) 600 mg in Glaucoma, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia.

Who is sponsoring NCT04088084?

NCT04088084 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia.

What drugs are being tested in NCT04088084?

Interventions in NCT04088084: palmitoylethanolamide (PEA) 600 mg.

Is NCT04088084 still recruiting?

NCT04088084 is currently completed. Last updated 12 September 2019.

Last reviewed 2019-09-12 · How we verify

NCT04088084

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Palmitoylethanolamide on Inner Retinal Function in Glaucoma Patients by Pattern Electroretinogram

Completed Phase 2 Last updated 12 September 2019

What this trial tests

Phase 2 trial testing palmitoylethanolamide (PEA) 600 mg in Glaucoma in 40 participants. Completed in 31 December 2017.

Timeline

9 March 2015

Primary endpoint
31 December 2017

31 December 2017

Quick facts

Lead sponsor	Fondazione IRCCS Policlinico San Matteo di Pavia
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	prevention
Enrollment	40
Start date	9 March 2015
Primary completion	31 December 2017
Estimated completion	31 December 2017

Drugs / interventions tested

palmitoylethanolamide (PEA) 600 mg

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The general purpose of the study is to evaluate the potential beneficial effects of PEA 600 mg supplementation on RGCs function in subjects with glaucoma by pattern electroretinogram after three months of therapy. Secondary objectives are to assess effects on intraocular pressure (IOP) values, if any; to record visual acuity, visual field, central corneal thickness (CCT), and Optical coherence tomography (OCT) (ganglion cell complex - GCC) changes, if any and to follow quality of life (QL) perception (general vision -GV and general health - GH of national eye instutute visual functioning questionnaire 25 items - NEI VFQ25)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroprotection provided by polyphenols and flavonoids in photoreceptor degenerative diseases.
de Lima-Vasconcellos TH, Bovi Dos Santos G, Móvio MI, Donnici GK, et al · · 2026 · cited 6× · PMID 40364630 · DOI 10.4103/nrr.nrr-d-24-01638
Challenging glaucoma with emerging therapies: an overview of advancements against the silent thief of sight.
Sarkis S, Chamard C, Johansen B, Daien V, et al · · 2025 · cited 5× · PMID 40206485 · DOI 10.3389/fmed.2025.1527319

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other Fondazione IRCCS Policlinico San Matteo di Pavia trials

Trials by the same sponsor.

NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04088084 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
Last refreshed: 12 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04088084.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing